About Organoid Sciences
Organoid Sciences is a publicly listed company based in Seongnam-si (South Korea) founded in 2019. Regenerative medicines for multiple diseases are developed using cannabinoid technology. Organoid Sciences has raised $38.96 million across 2 funding rounds from investors including Aju IB Investment, Atinum Investment and Dongwha Pharm. The company has 86 employees. Its chief executive, as recorded, is Jongman Yoo. Its focus areas include Life Sciences, Regenerative Medicine, Diversified and Diversified Pharmaceuticals.
Company details
Organoid Sciences was established in 2019 and is based in Seongnam-si, South Korea. Regenerative medicines targeting various diseases are developed through cannabinoid-based approaches. A pipeline of therapeutic solutions is advanced within the biotechnology sector, with operations focused on innovative applications for health conditions. Leadership is provided by CEO Jongman Yoo, supporting ongoing research and development efforts.
- Headquarters Seongnam-si, South Korea
- Employees 86
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website organoidrx.com
- Legal Name Organoidsciences Ltd.
- Annual Revenue$1.67 M (USD)23.21as on Dec 31, 2025
- Net Profit-$10.64 M (USD)-36.65as on Dec 31, 2025
- EBITDA-$10.22 M (USD)-34.98as on Dec 31, 2025
- Total Equity Funding$38.96M (USD)
in 2 rounds
- Latest Funding Round$32.54M (USD), Series B
Jan 2022
- InvestorsAju IB Investment
& 9 more
- Employee Count86
Funding Insights of Organoid Sciences
Organoid Sciences has successfully raised a total of $38.96M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $32.54 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $38.96M
- Total Rounds 2
- Last Round Series B — $32.54M
- First Round $6.43M
(Mar 2020)
- Investors Count 10
All 2 funding rounds of Organoid Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2022 | $32.54M | Series B | – | Korea Development Bank Europe, Dongwha Pharm | |
| Mar 2020 | $6.43M | Series A | – | Aju IB Investment |
10 investors in total: 10 institutional.
Investors in Organoid Sciences
Organoid Sciences has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Aju IB Investment, Atinum Investment and Dongwha Pharm.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| wiipco.com | ||||
Venture capital firm investing in tech startups | 2006 | kpartners.co.kr | Seoul, South Korea | |
VC firm investing in geographies such as South Korea | 1988 | atinuminvest.co.kr | Seoul, South Korea | |
Diversified investment, VC & financial advisory firm | 1974 | ajuib.co.kr | Seoul, South Korea | |
Growth-stage private equity investments are targeted across multiple sectors. | 1996 | lbinvestment.com | Seoul, South Korea | |
| envp.co.kr | ||||
Operates as a commercial bank providing deposits, loans, and payment services to customers. | 1989 | kdbbank.eu | Budapest, Hungary | |
Support is provided for medical, educational, and social welfare initiatives. | 1977 | asanfoundation.or.kr | Seoul, South Korea | |
Manufacturer of a wide range of medicines | 1897 | dong-wha.co.kr | Seoul, South Korea | |
An investment management firm handling diversified funds and portfolios. | 2008 | timefolio.co.kr | Seoul, South Korea |
Investor details for Organoid Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Organoid Sciences
1 people are tracked at Organoid Sciences (1 in leadership); the tracked headcount is 86.
| Name | Role | Group |
|---|---|---|
Jongman Yoo | CEO | Leadership |
Complete people profiles for Organoid Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Organoid Sciences
Organoid Sciences is a publicly listed company on the KRX with ticker symbol 476040 in South Korea, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 May 2025
- Listed onKRX: 476040
- Listed entityOrganoidsciences Ltd.
- Exchange sectorCommercial services
- ISINKR7476040001
- Share price6,270.00 KRW (-1.88% on the day) · 2026-10-14
- Market capitalisation42,083,004,098.00 KRW
- EPS (diluted, trailing year)-2,835.29 KRW
- Volume (last session)10,834
Financials of Organoid Sciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.41B KRW | -15.37B KRW | -14.76B KRW |
| 2024 | 1.95B KRW | -11.25B KRW | -10.93B KRW |
| 2023 | 1.59B KRW | -38.69B KRW | -8.65B KRW |
| 2022 | 438.2M KRW | -24.11B KRW | -9.75B KRW |
Detailed financial statements for Organoid Sciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Organoid Sciences
4 dated milestones of Organoid Sciences across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Organoid Sciences is founded.
- Funding First funding round of $6.4M.
- Funding Latest funding round, Series B, of $32.5M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Organoid Sciences
The website of Organoid Sciences (organoidrx.com) receives about 6K visits a month.
- Monthly visits6K
▼ 1.5% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Organoid Sciences
Complete news archive for Organoid Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Organoid Sciences
Organoid Sciences was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Organoid Sciences is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
Jongman Yoo is the CEO of Organoid Sciences, as recorded in our data.
Organoid Sciences is a funded company, having raised a total of $38.96M across 2 funding rounds to date. The company's 1st funding round was a Series A of $6.43M, raised on Mar 2020.
Organoid Sciences has 86 employees.
Annual revenue of Organoid Sciences is $1.67M as on Dec 31, 2025.
Organoid Sciences was established in 2019 and is based in Seongnam-si, South Korea. Regenerative medicines targeting various diseases are developed through cannabinoid-based approaches. A pipeline of therapeutic solutions is advanced within the biotechnology sector, with operations focused on innovative applications for health conditions. Leadership is provided by CEO Jongman Yoo, supporting ongoing research and development efforts.
Yes, Organoid Sciences is publicly traded on KRX under the ticker symbol 476040.
Organoid Sciences has 10 investors. Key investors include Aju IB Investment, Atinum Investment, Dongwha Pharm, LB Investment, and Company K Partners.